Clinical Trials Using Abiraterone Acetate

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Clinical trials are research studies that involve people. The clinical trials on this list are studying Abiraterone Acetate. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-23 of 23
  • Abiraterone Acetate in Treating Patients with Hormone-Resistant Prostate Cancer

    This randomized pilot clinical trial studies the best way to give abiraterone acetate in treating patients with hormone-resistant prostate cancer. Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as abiraterone acetate, may lessen the amount of androgen made by the body.
    Location: 10 locations

  • Apalutamide, Abiraterone Acetate, Prednisone, Leuprolide Acetate, and Stereotactic, Ultra-hypofractionated Radiation Therapy in Treating Patients with Very High Risk Prostate Cancer

    This phase II trial studies how well apalutamide, abiraterone acetate, prednisone, leuprolide acetate, and stereotactic, ultra-hypofractionated radiation therapy work in treating patients with very high risk prostate cancer. Hormone therapy using apalutamide, abiraterone acetate, prednisone, and leuprolide acetate may fight prostate cancer by lowering the amount of androgen the body makes and / or blocking the use of androgen by the tumor cells. Stereotactic, ultra-hypofractionated radiation therapy is a type of radiation therapy delivers higher doses of radiation over a shorter period of time and may kill more tumor cells and have fewer side effects. Giving apalutamide, abiraterone acetate, prednisone, and leuprolide acetate, and stereotactic, ultra-hypofractionated radiation therapy may work better in treating patients with prostate cancer.
    Location: 8 locations

  • Ipatasertib Plus Abiraterone Plus Prednisone / Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone / Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer

    The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of ipatasertib plus abiraterone and prednisone / prednisolone compared with placebo plus abiraterone and prednisone / prednisolone in participants with metastatic castrate-resistant prostate cancer (mCRPC).
    Location: 7 locations

  • A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer

    This is a randomized, open-label, three-arm, phase 3 study in men with biochemically recurrent prostate cancer and PSA doubling time ≤ 9 months at the time of study entry.
    Location: 7 locations

  • Study of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study)

    The purpose of this study is to evaluate the efficacy and safety of olaparib versus enzalutamide or abiraterone acetate in subjects with metastatic castration-resistant prostate cancer who have failed prior treatment with a new hormonal agent and have homologous recombination repair gene mutations.
    Location: 7 locations

  • Abiraterone Acetate with or without Cabazitaxel in Treating Patients with Metastatic Castration-Resistant Prostate Cancer

    This randomized phase II trial studies how well abiraterone acetate with cabazitaxel works and compares to abiraterone acetate alone in treating patients with prostate cancer that has spread to other places in the body (metastatic) and is resistant to surgical removal (castration-resistant). Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as abiraterone acetate, may lessen the amount of androgens made by the body. Drugs used in chemotherapy, such as cabazitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether abiraterone acetate is more effective with or without cabazitaxel in treating prostate cancer.
    Location: 5 locations

  • A Study of Rucaparib Verses Physician's Choice of Therapy in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency

    The purpose of this study is to determine how patients with metastatic castration-resistant prostate cancer, and evidence of a homologous recombination gene deficiency, respond to treatment with rucaparib verses treatment with physician's choice of abiraterone acetate, enzalutamide, or docetaxel.
    Location: 4 locations

  • AZD8186 First Time In Patient Ascending Dose Study

    This is a phase I, open-label, multicentre study of AZD8186 administered orally in patients with advanced castrate-resistant prostate cancer (CRPC), squamous non-small cell lung cancer (sqNSCLC), triple negative breast cancer (TNBC) and known PTEN-deficient / mutated or PIK3CB mutated / amplified advanced solid malignancies as monotherapy and in combination with abiraterone acetate or AZD2014.
    Location: 4 locations

  • Dose Escalation and Dose Expansion Study of GSK525762 in Combination With Androgen Deprivation Therapy and Other Agents in Subjects With Castrate-resistant Prostate Cancer

    The study aims to evaluate the combination of GSK525762 with other agents that have been shown to be effective in the treatment of CRPC or metastatic CRPC, including approved agents (e.g., abiraterone, enzalutamide) as well as investigational agents for mCRPC that have proven to show efficacy and can be combined based on complimentary mechanism of action. As a first step, the combination of GSK525762 will be evaluated as a combination with abiraterone or enzalutamide in men with metastatic or advanced castrate-resistant prostate cancer who have progressed on at least one line of prior androgen receptor (AR)-targeted therapy. This study is designed to determine the maximum tolerated dose (MTD) and recommended Phase II dose (RP2D) based on safety, tolerability, pharmacokinetic, and efficacy profiles of GSK525762 in combination with either abiraterone (Arm A) or enzalutamide (Arm B). Arm A and Arm B will further have 2 cohorts: A1, A2 and B1, B2 respectively based on prior lines of therapy (L2 [chemo-naive subjects treated with a second androgen-deprivation therapy] and Lx [subjects treated with both prior androgen-deprivation therapy and chemotherapy]). During dose escalation, both the treatment arms (A and B) will follow a modified Toxicity Probability Interval (mTPI) design. Approximately 130 subjects will be enrolled worldwide in this study. Subjects from both dose escalation and dose expansion may be combined to reach 30 subjects. The total duration of study will be approximately 2 to 3 years. A subject will be considered to have completed the study if they are followed until death.
    Location: 4 locations

  • A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

    The purpose of this study is to collect long term safety data in subjects who are continuing to derive clinical benefit from treatment with Enzalutamide from the subjects participation in an enzalutamide clinical study sponsored by Astellas or Medivation (i.e., parent study) which has completed, at a minimum, the primary analysis or the study specified evaluation period.
    Location: 5 locations

  • Abiraterone Acetate and Apalutamide before and after Surgery in Treating Patients with Intermediate-High Risk Prostate Cancer

    This phase II trial studies how well abiraterone acetate and apalutamide work in treating patients with intermediate-high risk prostate cancer before and after surgery. Androgens can cause the growth of prostate cancer cells. Drugs, such as abiraterone acetate and apalutamide, may lessen the amount of androgens made by the body.
    Location: 3 locations

  • Rapid Cycle Combination Therapy in Treating Patients with Metastatic Castrate-Resistant Prostate Cancer

    This phase II trial studies how well rapid cycle combination therapy works in treating patients with prostate cancer that has not responded to surgery or hormone therapy and has spread to other places in the body. Androgen can cause the growth of tumor cells. Antihormone therapy, such as abiraterone acetate and enzalutamide, may lessen the amount of androgen made by the body. Drugs used in the chemotherapy, such as radium Ra 223 dichloride, cabazitaxel, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Switching between different combinations of androgen deprivation therapy and chemotherapy after a short time may prevent drug resistance and help achieve better long-term control of prostate cancer.
    Location: 3 locations

  • Apalutamide, Abiraterone Acetate, and Prednisone in Treating Patients with Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer

    This phase II trial studies how well apalutamide, abiraterone acetate, and prednisone work in treating patients with castration-resistant prostate cancer that has spread to other parts of the body and have not had prior treatment with chemotherapy. Androgens, or male sex hormones, can cause the growth of prostate cancer cells. It is believed apalutamide may help stop or slow the growth of prostate cancer cell growth by blocking the male sex hormones. Abiraterone acetate is a drug that blocks the remaining or residual male sex hormones in the body that may be helping prostate cancer to grow. Prednisone may help abiraterone acetate work better by making tumor cells more sensitive to the drug. Giving apalutamide, abiraterone acetate, and prednisone together may work better in treating patients with prostate cancer.
    Location: Duke University Medical Center, Durham, North Carolina

  • Abiraterone Acetate, Olaparib, and Prednisone in Treating Patients with Metastatic Hormone-Resistant Prostate Cancer with DNA Repair Defects

    This partially randomized phase II trial studies how well abiraterone acetate, olaparib, and prednisone work in treating patients with prostate cancer that is resistant to hormones, has spread to other places in the body, and has deoxyribonucleic acid (DNA) repair defects. Abiraterone acetate and olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as prednisone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving abiraterone acetate, olaparib, and prednisone may work better in treating patients with prostate cancer.
    Location: Northwestern University, Chicago, Illinois

  • Apalutamide with or without Abiraterone Acetate, Gonadotropin-Releasing Hormone Analog, and Prednisone in Treating Patients with High-Risk Prostate Cancer Undergoing Surgery

    This randomized phase II trial studies how well apalutamide works with or without abiraterone acetate, gonadotropin-releasing hormone agonist, and prednisone in treating patients with high-risk prostate cancer undergoing surgery. Androgen can cause the growth of prostate cancer cells. Hormone therapy using apalutamide, abiraterone acetate, and gonadotropin-releasing hormone analog (GnRH agonist) may fight prostate cancer by lowering the levels of androgen the body makes. Prednisone may either kill the tumor cells or stop them from dividing. Giving apalutamide with or without abiraterone acetate, GnRH agonist and prednisone may work better in treating patients with prostate cancer.
    Location: 2 locations

  • A Phase II Neoadjuvant Study of Apalutamide, Abiraterone Acetate, Prednisone, Degarelix and Indomethacin in Men with Localized Prostate Cancer Pre-prostatectomy

    This phase II trial studies how well apalutamide, abiraterone acetate, prednisone, degarelix, and indomethacin work in treating patients with prostate cancer that has spread from where it started to nearby tissue or lymph nodes before surgery. Androgen can cause the growth of tumor cells. Hormone therapy using apalutamide, abiraterone acetate, prednisone, degarelix, and indomethacin may fight prostate cancer by lowering the amount of androgen the body makes and / or blocking the use of androgen by the tumor cells.
    Location: Fred Hutch / University of Washington Cancer Consortium, Seattle, Washington

  • Abiraterone Acetate, Niclosamide, and Prednisone in Treating Patients with Castration-Resistant Prostate Cancer

    This phase II trial studies the side effects and how well abiraterone acetate, niclosamide, and prednisone work in treating patients with castration-resistant prostate cancer. Androgens can cause the growth of prostate cells. Hormone therapy using abiraterone acetate may fight prostate cancer by lowering the amount of androgen the body makes. Niclosamide is a drug that may block another signal that can cause prostate cancer cell growth. Prednisone is a drug that can help lessen inflammation. Giving abiraterone acetate, niclosamide, and prednisone may be a better treatment for patients with castration-resistant prostate cancer.
    Location: University of California Davis Comprehensive Cancer Center, Sacramento, California

  • Abiraterone Acetate, Prednisone, and Apalutamide with or without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients with Metastatic Castration-Resistant Prostate Cancer

    This randomized phase II trial studies the side effects and how well abiraterone acetate, prednisone, and apalutamide work with or without ipilimumab or cabazitaxel and carboplatin in treating patients with castration-resistant prostate cancer that has spread to other places in the body. Androgens can cause the growth of prostate cancer cells. Drugs, such as abiraterone acetate and apalutamide may lessen the amount of androgens made by the body. Monoclonal antibodies, such as ipilimumab, may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as prednisone, cabazitaxel, and carboplatin work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether giving abiraterone acetate, prednisone, and apalutamide with or without ipilimumab or cabazitaxel and carboplatin may be a better way to treat patients with castration-resistant prostate cancer that has spread to other places in the body.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Adaptive Abiraterone Therapy for Metastatic Castration Resistant Prostate Cancer

    The purpose of this study is to find out if an on and off schedule of taking abiraterone would prolong the participant's cancer's response to this drug and maintain their functionality to perform their daily activities.
    Location: Moffitt Cancer Center, Tampa, Florida

  • Testosterone Therapy Followed by Enzalutamide or Abiraterone Acetate in Treating Patients with Prostate Cancer That Is Progressing on Combined Androgen Therapies

    This phase II trial studies how well testosterone therapy followed by enzalutamide or abiraterone acetate works in treating patients with prostate cancer that has become worse or spread on combined androgen therapies. Androgens, such as testosterone, can cause the growth of prostate cancer cells. Androgen therapies, such as enzalutamide and abiraterone acetate, suppress or block the production or action of testosterone. Rapid treatment with testosterone may make the cancer cells become sensitive to retreatment with enzalutamide or abiraterone acetate. Giving testosterone prior to enzalutamide or abiraterone acetate may have an effect on the growth of prostate cancer in men who have not responded to long term therapy to lower testosterone in their blood (castrating therapy).
    Location: Johns Hopkins University / Sidney Kimmel Cancer Center, Baltimore, Maryland

  • A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone Acetate

    The purpose of this study is to collect follow-up safety data from participants in completed abiraterone acetate studies for a maximum duration of 6 years.
    Location: See Clinical Trials.gov

  • Cognitive Assessment and MRI Program in Identifying Cognitive Effects of Androgen Receptor Directed Therapies in Patients with Advanced Prostate Cancer

    This clinical trial studies how well cognitive assessment and magnetic resonance imaging (MRI) program work in identifying cognitive effects of androgen receptor directed therapies such as abiraterone acetate and enzalutamide in patients with prostate cancer that has spread from where it started to other places in the body. Cognitive assessment and MRI program may help to assess the cognitive function of patients during treatment and identify genetic variations that might make patients more or less sensitive to cognitive changes during treatment for prostate cancer.
    Location: Vanderbilt University / Ingram Cancer Center, Nashville, Tennessee

  • Cardiorespiratory Function in Patients with Metastatic Hormone-Resistant Prostate Cancer Undergoing Treatment with Sipuleucel-T, Abiraterone Acetate, or Enzalutamide

    This pilot research trial studies cardiorespiratory function in patients with prostate cancer that has spread to other places in the body and does not respond to treatment with hormones, and are undergoing treatment with sipuleucel-T, abiraterone acetate, or enzalutamide. Both enzalutamide and abiraterone can cause cardiorespiratory side effects, however, exactly how these affect aerobic capacity has not been defined. In contrast, sipuleucel-T is not known to cause cardiorespiratory side effects. Understanding how each of these treatments influences aerobic capacity, which is also a predictor of quality of life, may allow for better treatment strategies for prostate cancer.
    Location: Duke University Medical Center, Durham, North Carolina